Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Deargen Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The prosecution data identifies 1 pending office action currently in progress. This action is assigned to 1 distinct examiner and 1 distinct art unit. This indicates that the company's current legal activity is focused on a specific technical niche.
The busiest examiner for this portfolio is ANDERSON-FEARS, KEENAN NEIL. This examiner is currently handling 1 pending office action. Given that the total number of pending actions is 1, ANDERSON-FEARS, KEENAN NEIL is responsible for the entire active prosecution pipeline for Deargen Inc. There are no other pending actions or examiners involved at this time.
The use of 1 distinct art unit for the single pending action suggests a consistent classification for the company's intellectual property. Practitioners can expect to work exclusively with ANDERSON-FEARS, KEENAN NEIL within that specific art unit. This concentration of 1 pending office action under 1 examiner provides a clear and singular point of contact for the company's current matters in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON-FEARS, KEENAN NEIL | 1 | 15.4% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18497318 | Method For Predicting Protein Binding Site | ANDERSON-FEARS, KEENAN NEIL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18497318 | Method For Predicting Protein Binding Site | ANDERSON-FEARS, KEENAN NEIL | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18497318 | Method For Predicting Protein Binding Site | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDeargen Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Keenan Neil Anderson-Fears has the most, with 1 of Deargen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
